Ocular Therapeutix (OCUL) Competitors $6.36 -0.64 (-9.14%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$6.60 +0.25 (+3.85%) As of 04/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. PTCT, ZLAB, OGN, ACLX, RNA, RARE, RYTM, SWTX, AKRO, and CRNXShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include PTC Therapeutics (PTCT), Zai Lab (ZLAB), Organon & Co. (OGN), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Rhythm Pharmaceuticals (RYTM), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. PTC Therapeutics Zai Lab Organon & Co. Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Rhythm Pharmaceuticals SpringWorks Therapeutics Akero Therapeutics Crinetics Pharmaceuticals PTC Therapeutics (NASDAQ:PTCT) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, community ranking, dividends, media sentiment, institutional ownership and valuation. Which has more volatility & risk, PTCT or OCUL? PTC Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Which has higher valuation & earnings, PTCT or OCUL? Ocular Therapeutix has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.23-$626.60M-$4.73-9.14Ocular Therapeutix$63.72M15.87-$80.74M-$1.26-5.05 Does the MarketBeat Community prefer PTCT or OCUL? PTC Therapeutics received 129 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. However, 70.18% of users gave Ocular Therapeutix an outperform vote while only 61.92% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformPTC TherapeuticsOutperform Votes56961.92% Underperform Votes35038.08% Ocular TherapeutixOutperform Votes44070.18% Underperform Votes18729.82% Do insiders & institutionals have more ownership in PTCT or OCUL? 59.2% of Ocular Therapeutix shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 3.5% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer PTCT or OCUL? PTC Therapeutics currently has a consensus price target of $63.77, suggesting a potential upside of 47.48%. Ocular Therapeutix has a consensus price target of $16.38, suggesting a potential upside of 157.47%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is PTCT or OCUL more profitable? PTC Therapeutics has a net margin of -50.32% compared to Ocular Therapeutix's net margin of -283.74%. PTC Therapeutics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics-50.32% N/A -16.44% Ocular Therapeutix -283.74%-45.18%-30.87% Does the media favor PTCT or OCUL? In the previous week, PTC Therapeutics had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 13 mentions for PTC Therapeutics and 8 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.70 beat PTC Therapeutics' score of 0.65 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOcular Therapeutix beats PTC Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$6.32B$5.24B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-4.826.7221.2017.46Price / Sales15.87186.91356.3585.24Price / CashN/A65.6738.1634.64Price / Book8.055.576.233.79Net Income-$80.74M$141.67M$3.20B$247.10M7 Day Performance-16.09%-11.44%-8.32%-7.32%1 Month Performance-2.15%-14.59%-3.36%-10.20%1 Year Performance-24.91%-18.30%2.72%-7.41% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.2301 of 5 stars$6.36-9.1%$16.38+157.5%-24.9%$1.01B$63.72M-4.82230News CoveragePTCTPTC Therapeutics3.7244 of 5 stars$50.96-6.0%$63.77+25.1%+55.4%$4.02B$806.78M-8.581,410News CoverageGap DownHigh Trading VolumeZLABZai Lab1.9753 of 5 stars$36.14-3.1%$47.37+31.1%+105.6%$3.96B$398.99M-13.051,950Insider TradeNews CoverageGap DownHigh Trading VolumeOGNOrganon & Co.4.656 of 5 stars$14.92+2.8%$20.80+39.4%-27.1%$3.85B$6.40B4.4810,000Positive NewsGap DownACLXArcellx1.9329 of 5 stars$65.60-3.5%$108.46+65.3%-5.5%$3.60B$107.94M-92.3980News CoveragePositive NewsGap DownRNAAvidity Biosciences2.4621 of 5 stars$29.52-6.6%$66.69+125.9%+12.2%$3.55B$10.90M-10.25190Insider TradeGap DownHigh Trading VolumeRAREUltragenyx Pharmaceutical4.305 of 5 stars$36.21-4.3%$92.79+156.2%-31.1%$3.35B$560.23M-5.711,310News CoveragePositive NewsGap DownRYTMRhythm Pharmaceuticals4.3138 of 5 stars$52.97-3.3%$69.46+31.1%+17.1%$3.35B$130.13M-12.23140Gap DownSWTXSpringWorks Therapeutics1.841 of 5 stars$44.13-6.9%$73.20+65.9%-12.2%$3.31B$191.59M-12.68230Positive NewsGap DownAKROAkero Therapeutics4.0429 of 5 stars$40.48-5.2%$76.29+88.5%+59.9%$3.22BN/A-10.7930Gap DownCRNXCrinetics Pharmaceuticals4.2815 of 5 stars$33.54-3.4%$73.00+117.7%-42.4%$3.12B$1.04M-8.99210News CoveragePositive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies PTCT Competitors ZLAB Competitors OGN Competitors ACLX Competitors RNA Competitors RARE Competitors RYTM Competitors SWTX Competitors AKRO Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCUL Stock Free OCUL Stock Alerts